Opinion
M&A Practical Insights: A CFO Action Guide from Due Diligence to Integration
RoseRyan President David Roberson, based on his practical experience with the company's acquisition by ZRG, distills four key points in M&A—'cast a wide net, set priorities, prepare for all contingencies, and plan for the long term'—and provides actionable recommendations.
SEC's Proposed Climate Disclosure Rules: CFOs Should Listen to Investors
As the SEC's proposed climate disclosure rules advance, CFOs face compliance pressure, but the author points out this is also a business opportunity. By implementing an ESG data management platform, companies can meet investors' demands for accurate, complete, and auditable data and establish a competitive advantage. A survey shows that 69% of investors have a consensus on the attributes of investment-grade ESG data, but most companies' data credibility is insufficient.
Collaborative Business Models: The Win-Win Path for Enterprises and Customers
Collaborative business models are on the rise, where customers avoid prepaid costs and enterprises take a share of savings or revenue. Using Redaptive and BusPatrol as examples, the article examines their technology-driven nature, market acceptance, and accounting valuation challenges.
Why Cloud Cost Anomaly Detection Has Become a Business Necessity: Real-Time Monitoring Is Indispensable
The risk of runaway cloud costs is increasingly prominent, making real-time anomaly detection a key defense for enterprise financial health. Based on industry surveys and expert insights, this article analyzes common triggers such as configuration errors, explains the value of continuous monitoring, and evaluates the applicability boundaries of AWS native tools versus specialized solutions.
Three Steps to Achieving 'Zen' Management of Uncontrolled Spending
Uncontrolled spending accounts for approximately 80% of corporate transaction volume and 20% of total expenditure, but is breaking the 80/20 rule. Emburse CFO Adriana Carpenter believes that SaaS adoption and remote work are the drivers, and that finance departments should abandon mandatory control over employee behavior, instead achieving 'Zen' management through empathy and automation.
Growth, Inflation, and Capital Access: The Triple Game CFOs Face in 2022
Based on CFO roundtable discussions and Pulse Survey data, Wes Bricker, Vice Chairman of PwC US, analyzes the core challenges CFOs face in 2022: inflationary pressures (79% of CFOs expect inflation to remain high by year-end), talent competition (83% view it as key to growth), and ESG strategy implementation (only 34% of CFOs consider it important). The article emphasizes that CFOs need cross-departmental collaboration to balance short-term cost pressures with long-term value creation.
Three Ways to Use Recurring Revenue to Finance Business Growth
When a business is ready to expand, a lack of liquidity often becomes a major obstacle. In addition to traditional equity financing and debt financing, more and more companies are exploring ways to use their own recurring revenue to support growth. This article introduces three approaches: slow accumulation, revenue-based financing (RBF), and treating recurring revenue as a tradable asset. Each approach has its own applicable scenarios and potential risks, and businesses need to choose carefully based on their own circumstances.
Fairness Opinion or Providing Assurance for SPAC Merger Target Companies
In SPAC mergers, target company management faces litigation risks stemming from conflicts of interest between sponsors and investors. The Delaware court in the Multiplan case adopted the 'entire fairness' standard, weakening the traditional 'cleansing' effect of shareholder votes. Obtaining an independent fairness opinion has become a low-cost, effective protective measure, and it is worth considering as a closing condition for target companies.
Analysis of the Impact of New R&D Tax Rules on Life Sciences Companies
Starting January 1, 2022, U.S. research and development expenditures must be capitalized and amortized over time, replacing the previous immediate deduction. This change significantly impacts life sciences companies, particularly early-stage firms, in terms of tax and financial reporting. KPMG experts analyze the scope of the rules, financial reporting implications, software treatment, and future legislative uncertainty.
